Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prednimustine therapy for advanced prostatic cancer.

R Catane, J H Kaufman, S Madajewicz

    British Journal of Urology
    |February 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Preliminary Experience with Short Course High-Dose Mitoxantrone in Combination with High-Dose Cytarabine in Patients with Acute Leukemia and Blastic Phase of Chronic Myelogenous Leukemia.

    Leukemia & lymphoma·2016
    Same author

    Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule.

    Leukemia & lymphoma·2016
    Same author

    Relationship between response rate and median survival in patients with advanced nonsmall cell lung-cancer - comparison of onconase(r) with other anticancer agents.

    International journal of oncology·2011
    Same author

    Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES.

    International journal of oncology·2011
    Same author

    Sub-epitopic dissection of HCV E1315-328HRMAWDMMMNWSPT sequence by similarity analysis.

    Amino acids·2007
    Same author

    Anti-carcinogenic and anti-metastatic properties of indole-3-carbinol in prostate cancer.

    Oncology reports·2004
    Same journal

    Removal of ureteric calculus by the ureteric corkscrew in a case of calculous anuria.

    British journal of urology·2010
    Same journal

    Obstructive anuria, probably due to calculus.

    British journal of urology·2010
    Same journal

    The incidence of signs of renal injury following prolonged burial under debris in an unselected series of 764 airraid casualties admitted to hospital.

    British journal of urology·2010
    Same journal

    Contribution to the etiology of acquired fibrosis of the bladder neck.

    British journal of urology·2010
    Same journal

    True infective abacterial pyuria.

    British journal of urology·2010
    Same journal

    A malignant right kidney removed at operation, together with a short length of the vena cava.

    British journal of urology·2010
    See all related articles

    Daily oral prednimustine, combining prednisolone and chlorambucil, showed a 35% subjective response rate in advanced prostate cancer patients. This treatment offered moderate toxicity and potential utility for advanced prostate cancer management.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Advanced, hormonal-resistant prostate cancer presents significant treatment challenges.
    • Limited effective therapeutic options exist for patients with progressive disease.

    Purpose of the Study:

    • To evaluate the efficacy and toxicity of daily oral prednimustine in patients with advanced, hormonal-resistant prostate cancer.
    • To assess subjective and objective response rates to prednimustine therapy.

    Main Methods:

    • A cohort of 23 patients with advanced, hormonal-resistant prostate cancer received daily oral prednimustine.
    • Prednimustine is a combination of prednisolone and chlorambucil.
    • Patient responses were monitored for subjective improvements and objective tumor regression.

    Main Results:

    Related Experiment Videos

    • 8 out of 23 patients (35%) reported subjective improvements, including pain relief and better well-being.
    • 3 patients demonstrated objective evidence of tumor regression.
    • Clinical toxicity was generally moderate, with occasional myelosuppression observed.

    Conclusions:

    • Daily oral prednimustine demonstrates potential as a treatment for advanced prostate cancer.
    • The drug is well-tolerated with manageable toxicity, making it a viable option alone or in combination therapies.
    • Further investigation into prednimustine's role in advanced prostate cancer is warranted.